Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer
{{output}}
The use of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of patients with germline BRCA mutations (gBRCAm) and breast cancer, both in the early and advanced settings, is a success of genomically-directed treatment. These agents have been show... ...
